1. Parkin DM, Bray F, Ferlay J, Pisani P. 3. Moore SR, Johnson NW, Pierce AM, Estimating the world cancer burden: Wilson DF. The epidemiology of tongue Globocan 2000. Int J Cancer 2001;94: cancer: a review of global incidence. Oral 153–6. Dis 2000;6:75–84.
2. Slaughter DP, Southwick HW, Smejkal W. 4. Prasad AS, Beck FW, Doerr TD, Shamsa Field cancerization in oral stratified FH, Penny HS, Marks SC, Kaplan J, Kucuk squamous epithelium; clinical implications O, Mathog RH. Nutritional and zinc status of multicentric origin. Cancer 1953;6:963–8. of head and neck cancer patients: an
interpretive review. J Am Coll Nutr 1998; 17:409–18.
5. Buntzel J, Bruns F, Glatzel M, Garayev A, Mucke R, Kisters K, Schafer U, Schonekaes K, Micke O. Zinc concentrations in serum during head and neck cancer progression. Anticancer Res 2007;27:1941–3.
6. Abnet CC, Lai B, Qiao YL, Vogt S, Luo XM, Taylor PR, Dong ZW, Mark SD, Dawsey SM. Zinc concentration in esophageal biopsy specimens measured by x-ray fluorescence and esophageal cancer risk. J Natl Cancer Inst 2005;97:301–6.
7. Doerr TD, Marks SC, Shamsa FH, Mathog RH, Prasad AS. Effects of zinc and nutritional status on clinical outcomes in head and neck cancer. Nutrition 1998;14: 489–95.
8. Vallee BL, Falchuk KH. The biochemical basis of zinc physiology. Physiol Rev 1993; 73:79–118.
9. Rink L, Haase H. Zinc homeostasis and immunity. Trends Immunol 2007;28:1–4.
10. O’Halloran TV. Transition metals in control of gene expression. Science 1993; 261:715–25.
11. Prasad AS, Beck FW, Snell DC, Kucuk O. Zinc in cancer prevention. Nutr Cancer 2009;61:879–87.
12. Maret W, Sandstead HH. Zinc requirements and the risks and benefits of zinc supplementation. J Trace Elem Med Biol 2006;20:3–18.
13. Fong LY, Zhang L, Jiang Y, Farber JL. Dietary zinc modulation of COX-2 expression and lingual and esophageal carcinogenesis in rats. J Natl Cancer Inst 2005;97:40–50.
14. Taccioli C, Wan SG, Liu CG, Alder H, Volinia S, Farber JL, Croce CM, Fong LY. Zinc replenishment reverses overexpression of the proinflammatory mediator S100A8 and esophageal preneoplasia in the rat. Gastroenterology 2009;136:953–66.
15. Fong LY, Nguyen VT, Farber JL. Esophageal cancer prevention in zinc- deficient rats: rapid induction of apoptosis by replenishing zinc. J Natl Cancer Inst 2001;93:1525–33.
16. Fong LY, Jiang Y, Riley M, Liu X, Smalley KJ, Guttridge DC, Farber JL. Prevention of upper aerodigestive tract cancer in zinc- deficient rodents: inefficacy of genetic or pharmacological disruption of COX-2. Int J Cancer 2008;122:978–89.
17. William WN, Jr, Heymach JV, Kim ES, Lippman SM. Molecular targets for cancer chemoprevention. Nat Rev Drug Discov 2009;8:213–25.
18. Zimmermann KC, Sarbia M, Weber AA, Borchard F, Gabbert HE, Schror K. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 1999;59: 198–204.
19. Renkonen J, Wolff H, Paavonen T. Expression of cyclo-oxygenase-2 in human tongue carcinoma and its precursor lesions. Virchows Arch 2002;440:594–7.
20. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000;69:145–82.
21. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, Evans JF, Taketo MM. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87: 803–9.
22. Menter DG, Schilsky RL, Dubois RN. Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clin Cancer Res 2010;16:1384–90.
23. Dawson SJ, Michael M, Biagi J, Foo KF, Jefford M, Ngan SY, Leong T, Hui A, Milner AD, Thomas RJ, Zalcberg JR. A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer. Invest New Drugs 2007;25:123–9.
24. Bernier J, Bentzen SM, Vermorken JB. Molecular therapy in head and neck oncology. Nat Rev Clin Oncol 2009;6: 266–77.
25. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009;4:44–57.
26. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 1998;17:857–72.
27. Kim MM, Glazer CA, Mambo E, Chatterjee A, Zhao M, Sidransky D, Califano JA. Head and neck cancer cell lines exhibit differential mitochondrial repair deficiency in response to 4NQO. Oral Oncol 2006;42:201–7.
28. Ide F, Oda H, Nakatsuru Y, Kusama K, Sakashita H, Tanaka K, Ishikawa T. Xeroderma pigmentosum group A gene action as a protection factor against 4- nitroquinoline 1-oxide-induced tongue carcinogenesis. Carcinogenesis 2001;22: 567–72.
29. Tang XH, Knudsen B, Bemis D, Tickoo S, Gudas LJ. Oral cavity and esophageal carcinogenesis modeled in carcinogen- treated mice. Clin Cancer Res 2004;10: 301–13.
30. Tiano HF, Loftin CD, Akunda J, Lee CA, Spalding J, Sessoms A, Dunson DB, Rogan EG, Morham SG, Smart RC, Langenbach R. Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Res 2002;62: 3395–401.
31. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005;5:749–59.
32. Gebhardt C, Nemeth J, Angel P, Hess J. S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol 2006;72: 1622–31.